Synbody Biotechnology is developing a drug-discovery platform that uses unstructured, synthetically produced peptides to generate synthetic antibodies ('synbodies') that bind specifically to targets of interest. The company’s core product is the synbody platform aimed at discovering ligands for therapeutic development across cancer, diabetes, cardiovascular, central nervous system, and infectious diseases. The technology was developed at Arizona State University and the company has been supported with over $10 million in funding to date. Leadership includes president Paul Hallenbeck, Ph.D., and co-founder and vice president of R&D Kevin Burroughs, Ph.D. Synbody relocated to Farmington, Connecticut from Pennsylvania and has collaborations with the University of Connecticut and Hartford Hospital, participating in UConn’s Technology Incubator Program with lab operations in incubator space at the UConn Health Center. Financially, the company recently raised $250K from Connecticut Innovations following an earlier $750K CI Seed Investment Fund commitment. Synbody Biotechnology advances a patent-pending drug discovery platform that uses unstructured, synthetically produced peptides to generate "Synbodies" (synthetic antibodies). The technology was developed at Arizona State University and targets a broad range of therapeutic areas including oncology, cardiovascular, central nervous system, diabetes and infectious disease. The company is led by president and CEO Paul Hallenbeck, Ph.D., with co‑founders Kevin Burroughs, Ph.D., Stephen Johnston, Ph.D., and Chris Diehnelt, Ph.D. Synbody is based in Farmington, Connecticut. Its platform has been supported with over $10m in funding to date. The company recently received additional seed funding to advance its discovery work and organizational growth.

Total raised

$1M

Funding rounds

2

Latest round

Equity

Latest activity

Dec 2012